MiRNAs profiling studies in glioblastoma "ex vivo" specimens

Table 1: MiRNAs profiling studies in glioblastoma "ex vivo" specimens

Number of Human miRNAs analyzed	Samples setting	Methods	Up-regulated miRNAs	Down-regulated miRNAs	References
245	9 fresh GBMs vs 9 ANBs	Microarray	-10b, -130a, -221, -125b-1, -125b-2, -9-2, -21, -25, -123	-128a, -181c, -181a, -181b	[15]
180	3 fresh GBMs vs 8 NBs	Microarray	-21, -138, -347, -291-5', -135	-202	[24]
534	240 GBMs vs 10 NBs (data from TCGA)	Microarray	-15a, -15b, -16, -17-5p, -25, -92, -93, -106a, -106b, -320, -502, -532, -590, -660	-487a, -323, -329, -218	[28]
474	3 fresh GBMs vs 2 NBs	Microarray	-10b, -182, -10a, -183, 21, -148a, -503, -505, -451, -144, -542-5p, -542-3p, -26a, -142-3p, -199b, -15b, -550, -25, 9*, -92b, -142-5p, -27a, -23a, -486, -362, -532, -93, -106b, -223	None found	[34]
756	26 fresh GBMs vs 13 AAs	Microarray	-16, -21, -22, -24, -34a, -126, -142-5p, -143, -146b-5p, -155, -193a-3p, -199a/b-3p, -335, 376c, -381, -451, -509-3-5p, -513a-5p, -552, -886-3p/5p	-128, -219-2-3p	[43]
127	3 fresh GBMs vs ANB	Microarray	-10b, -21, -183, -92b, -106b	-302c , -379, -329, -134, -369-3p	[44]
305	222 GBMs vs 10 NBs (data from TCGA)	Microarray	-20a, -106a, -17-5p, -148a, -146b, -200b, -193a	-221, -222, -31	[49]
NS	261 GBMs vs 10 NBs (data from TCGA)	Microarray	-21, -10b, -210, -27a, -25, -15b, -23a, -92b, -106b, -92, -155, -93, -339, -494, -565, -130b, -34a, -16, -20a, -320, -106a, -19b, -100, -17-5p, -424	-124a, -139, -134, -7, -218, -338, -129, 2-19, -128b, -128a, -136, -410, -138, -29b, -29c, -491, -132, -379, -377, -149, -769-5p, -330, -323	[50]
1145	82 fresh GBMs vs 5 NBs	Microarray	-518b, -566	-181d, -524-5p, -1227	[55] †
282	12 fresh GBMs and 12 fresh O vs 4 fresh NBs	Microarray and qRT-PCR	-21, -155, let-7f, let-7a, -16, -15b, -9, -210	-132, -128, -7, -330-3p, -139-5p, -124	[37]
8	10 fresh GBMs, 10 AAs, 8 LGAs, vs 4 NBs	qRT-PCR	-21, -221	-181b	[25]
365	8 fresh GBMs vs 4 AAs	qRT-PCR	-15b, -21, -135b, -196a, -196b, -363	-105, -128b, -184, -302b, -302d, -367, -383, -504, -517c, -601	[32]
875 §	3 fresh GBMs vs 3 NBs	NGS	-10b, -96, -10b, -182, -135a, -21*, -21, -542-3p, -148a, -92b	-433, -7-1, -129, -628-5p, -935, -218, -31, -876-3p, -1258, -132	[33]
157	4 fresh secondary GBMs vs LGGs	qRT-PCR	-9, -15a, -16, -17, -19a, -20a, -21, -25, -28, -130b, -140, -210	-184, -328	[40]
192	4 fresh GBMs, 4 AAs vs 4 NBs	qRT-PCR	-10b, -21, -155, -210	-7, -31, -107, -124, -124b, -129, -137, -138, -139, -187, -203, -218, -101, -128a, -132, -133a, -133b, -149, -153, -154*, -185, -29b, -323, -328, -330	[47]
Whole-genome small RNA sequencing (according to miRBASE v 16.0)	6 fresh GBMs vs 3 NBs	NGS	-10b, -10b, -891a, -93, -196b, -21, -320d, -217, -4448, -25, -660, -21, -320c, -296-3p, -92b, -10a, -92a, let-7i, -148a	-124, -95, -132, -139-5p, -7, -543, let-7d, -323-3p, -128, -598, -103a, -103b, -139-3p, -487b, -873, -323b-3p, -1381, -301b, -107, -411-3p, -124, -342-3p, -379*, -212, let-7g, -153, -181d, -22, -889, -885-5p, -379, -138, let-7e, -218, -221, -136, -24, -4787-3p, -126, -548i, -382, -1270, -495, -2392, -1273d, -767-5p, -770-5p, -504, -490-3p	[48]
>1000	35 FFPE GBMs: short-term vs long-term survivors	Microarray	miR-3163	-539, -1305, -1260, let-7a	[63]
8	22 FFPE-dissected GBMs vs 6 NBs	qRT-PCR	-21, -125b	-128a, -222, -221, -181b, -181c, -181a	[65]
8	38 FFPE GBMs vs 6 NBs and 4 commercial RNAs	qRT-PCR	-196a, -196b, -21	-128a, -221, -195, -222, -181c	[66]

Only miRNAs showed a fold change greater than or equal to two-fold, were considered. GBM: Glioblastoma, AA: Anaplastic Astrocytoma, NB: Normal Brain, ANB: Adjacent Normal Brain, LGA: Low Grade Astrocytoma, LGG: Low Grade Glioma, O: Oligodendroglioma, DA: Diffuse Astrocytoma, NS: Not Specified, NGS: Next Generation Sequencing, TGCA: The Cancer Genome Atlas (TCGA) Datasets, FFPE: Formalin-Fixed Paraffin-Embedded. In bold, miRNAs reported up- or down-regulated in at least 3 studies. § Only the most 10 up- or down-regulated miRNAs are reported, ^† The authors considered a cut-off fold change ≥ 1.5.